These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 29435734

  • 1. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J, Huang Q, Xu J, Huang J, Wang J, Zhong W, Chen W, Lin X, Lin X.
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [Abstract] [Full Text] [Related]

  • 2. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L, Liu Y, Zhao TL, Li ZZ, He JY, Zhang BJ, Du HZ, Jiang JW, Yuan ST, Sun L.
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [Abstract] [Full Text] [Related]

  • 3. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
    Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.
    Blood; 2016 Aug 04; 128(5):667-79. PubMed ID: 27268090
    [Abstract] [Full Text] [Related]

  • 4. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y, Li W, Ling Z, Hu Q, Fan Z, Cheng B, Tao X.
    Cancer Med; 2020 May 04; 9(10):3489-3499. PubMed ID: 32162845
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, Kaminska K, Marusiak AA, Nowis D.
    Cancer Lett; 2021 Jun 01; 507():13-25. PubMed ID: 33713737
    [Abstract] [Full Text] [Related]

  • 6. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
    Wang C, Wu J, Wang Z, Yang Z, Li Z, Deng H, Li L, Peng X, Feng M.
    Biomaterials; 2018 Nov 01; 183():77-92. PubMed ID: 30149232
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
    Hara Y, Minami Y, Yoshimoto S, Hayashi N, Yamasaki A, Ueda S, Masuko K, Masuko T.
    Cancer Med; 2020 Jan 01; 9(1):302-312. PubMed ID: 31709772
    [Abstract] [Full Text] [Related]

  • 8. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JE, Holst J.
    J Pathol; 2015 Jul 01; 236(3):278-89. PubMed ID: 25693838
    [Abstract] [Full Text] [Related]

  • 9. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y, Massard PA, Vucetic M, Giuliano S, Tambutté E, Durivault J, Vial V, Endou H, Wempe MF, Parks SK, Pouyssegur J.
    J Biol Chem; 2018 Feb 23; 293(8):2877-2887. PubMed ID: 29326164
    [Abstract] [Full Text] [Related]

  • 10. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z, Liu R, Shuai Y, Huang Y, Jin R, Wang X, Luo J.
    Br J Cancer; 2020 Jan 23; 122(1):82-93. PubMed ID: 31819178
    [Abstract] [Full Text] [Related]

  • 11. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
    Zhou P, Liang X, Zhou C, Qin J, Hou C, Zhu Z, Zhang W, Wang S, Zhong D.
    J Mater Chem B; 2019 Sep 11; 7(35):5363-5375. PubMed ID: 31403158
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting glutamine transport to suppress melanoma cell growth.
    Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE, Holst J.
    Int J Cancer; 2014 Sep 01; 135(5):1060-71. PubMed ID: 24531984
    [Abstract] [Full Text] [Related]

  • 14. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, Harvey K, Beith JM, Selinger CI, O'Toole SA, Rasko JE, Holst J.
    Oncogene; 2016 Jun 16; 35(24):3201-8. PubMed ID: 26455325
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Guo H, Xu Y, Wang F, Shen Z, Tuo X, Qian H, Wang H, Wang K.
    Oncol Rep; 2018 Dec 16; 40(6):3725-3733. PubMed ID: 30272366
    [Abstract] [Full Text] [Related]

  • 17. The pro-proliferative effect of interferon-γ in breast cancer cell lines is dependent on stimulation of ASCT2-mediated glutamine cellular uptake.
    Silva C, Andrade N, Rodrigues I, Ferreira AC, Soares ML, Martel F.
    Life Sci; 2021 Dec 01; 286():120054. PubMed ID: 34662550
    [Abstract] [Full Text] [Related]

  • 18. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H, Li X, Lu Y, Qiu S, Fan Z.
    Cancer Lett; 2016 Oct 10; 381(1):23-30. PubMed ID: 27450723
    [Abstract] [Full Text] [Related]

  • 19. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
    Wang W, Pan H, Ren F, Chen H, Ren P.
    Biosci Rep; 2022 Mar 31; 42(3):. PubMed ID: 35237783
    [Abstract] [Full Text] [Related]

  • 20. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
    Zhou G, Qin M, Zhang X, Yang J, Yu H.
    Gastroenterol Hepatol; 2021 Jan 31; 44(1):1-12. PubMed ID: 33039171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.